Fulcrum Therapeutics Inc
NASDAQ:FULC
Fulcrum Therapeutics Inc
Research & Development
Fulcrum Therapeutics Inc
Research & Development Peer Comparison
Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors
Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Fulcrum Therapeutics Inc
NASDAQ:FULC
|
Research & Development
-$71.8m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Research & Development
-$15.2B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-6%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Research & Development
-$9.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-10%
|
|
Pfizer Inc
NYSE:PFE
|
Research & Development
-$10.6B
|
CAGR 3-Years
-74%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-5%
|
|
Merck & Co Inc
NYSE:MRK
|
Research & Development
-$29.5B
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-15%
|
|
Eli Lilly and Co
NYSE:LLY
|
Research & Development
-$9.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-6%
|
See Also
What is Fulcrum Therapeutics Inc's Research & Development?
Research & Development
-71.8m
USD
Based on the financial report for Dec 31, 2023, Fulcrum Therapeutics Inc's Research & Development amounts to -71.8m USD.
What is Fulcrum Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-23%
Over the last year, the Research & Development growth was 6%. The average annual Research & Development growth rates for Fulcrum Therapeutics Inc have been -7% over the past three years , -23% over the past five years .